EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay

Chiara Orlandi iD, Giuseppe Stefanetti, Simone Barocci, Gloria Buffi, Aurora Diotallevi iD, Ettore Rocchi iD, Marcello Ceccarelli, Sara Peluso iD, Daniela Vandini, Eugenio Carlotti, Mauro Magnani iD, Luca Galluzzi iD und 1 weitere

Viruses · 13.05.2023 · 15 (5) · 1162

DOI: 10.3390/v15051162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 13.05.2023. Verfasst von Chiara Orlandi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomolecular Sciences, Section of Biochemistry and Biotechnology, University of Urbino Carlo Bo, Via Arco d'Augusto 2, 61032 Fano, PU, …. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo sanzioni SPSAL (Servizio di Prevenzione e Sicurezza Ambienti di Lavoro) art.42 L.R. 11/2001, Fondi d’Ateneo Covid-Lab..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The humoral response after vaccination was evaluated in 1248 individuals who received different COVID-19 vaccine schedules. The study compared subjects primed with adenoviral ChAdOx1-S (ChAd) and boosted with BNT162b2 (BNT) mRNA vaccines (ChAd/BNT) to homologous dosing with BNT/BNT or ChAd/ChAd vaccines. Serum samples were collected at two, four and six months after vaccination, and anti-Spike IgG responses were determined. The heterologous vaccination induced a more robust immune response than the two homologous vaccinations. ChAd/BNT induced a stronger immune response than ChAd/ChAd at all time points, whereas the differences between ChAd/BNT and BNT/BNT decreased over time and were not significant at six months. Furthermore, the kinetic parameters associated with IgG decay were estimated by applying a first-order kinetics equation. ChAd/BNT vaccination was associated with the longest time of anti-S IgG negativization and with a slow decay of the titer over time. Finally, analyzing factors influencing the immune response by ANCOVA analysis, it was found that the vaccine schedule had a significant impact on both the IgG titer and kinetic parameters, and having a Body Mass Index (BMI) above the overweight threshold was associated with an impaired immune response. Overall, the heterologous ChAd/BNT vaccination may offer longer-lasting protection against SARS-CoV-2 than homologous vaccination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansLongitudinal StudiesBNT162 VaccineSARS-CoV-2VaccinationChAdOx1 nCoV-19Immunoglobulin GAntibodies, ViralAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19SARS-CoV-2anti-Spike IgG responseantibody decayheterologous vaccination

Substanzen

COVID-19 VaccinesBNT162 VaccineChAdOx1 nCoV-19Immunoglobulin GAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Biomolecular Sciences, Section of Biochemistry and Biotechnology, University of Urbino Carlo Bo, Via Arco d'Augusto 2, 61032 Fano, PU, Italy.
  • Laboratorio Covid, University of Urbino Carlo Bo, Via Arco d'Augusto 2, 61032 Fano, PU, Italy.
  • Department of Clinical Pathology, Azienda Sanitaria Unica Regionale Marche Area Vasta 1 (ASUR Marche AV1), Viale Comandino 70, 61029 Urbino, PU, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40138 Bologna, BO, Italy.
  • Department of Physics and Astronomy, University of Bologna, Viale Berti Pichat 6/2, 40127 Bologna, BO, Italy.
  • Department of Prevention, ASUR Marche AV1, Viale Comandino 21, 61029 Urbino, PU, Italy.

ORCID-Profile: Chiara Orlandi, Aurora Diotallevi, Ettore Rocchi, Sara Peluso, Mauro Magnani, Luca Galluzzi, Anna Casabianca

Förderung

  • Fondo sanzioni SPSAL (Servizio di Prevenzione e Sicurezza Ambienti di Lavoro) art.42 L.R. 11/2001
  • Fondi d’Ateneo Covid-Lab.

Zitieren

APA

Orlandi, C., Stefanetti, G., Barocci, S., Buffi, G., Diotallevi, A., Rocchi, E., Ceccarelli, M., Peluso, S., Vandini, D., Carlotti, E., Magnani, M., Galluzzi, L., & Casabianca, A. (2023). Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay. Viruses, 15(5), 1162. https://doi.org/10.3390/v15051162

Vancouver

Orlandi C, Stefanetti G, Barocci S, Buffi G, Diotallevi A, Rocchi E, et al. Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay. Viruses. 2023;15(5):1162. doi:10.3390/v15051162

BibTeX
@article{Orlandi2023,
  author = {Orlandi, Chiara and Stefanetti, Giuseppe and Barocci, Simone and Buffi, Gloria and Diotallevi, Aurora and Rocchi, Ettore and Ceccarelli, Marcello and Peluso, Sara and Vandini, Daniela and Carlotti, Eugenio and Magnani, Mauro and Galluzzi, Luca and Casabianca, Anna},
  title = {Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay},
  journal = {Viruses},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1162},
  doi = {10.3390/v15051162}
}
Kostenlos starten →